Korro Bio (KRRO) Cash from Financing Activities (2018 - 2026)

Korro Bio's Cash from Financing Activities history runs 9 years deep, the most recent figure standing at $88.2 million for Q1 2026.

• Quarterly Cash from Financing Activities rose 51186.05% year-over-year to $88.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $88.7 million (up 27.87% YoY) and the FY2025 annual result came in at $685000.0, down 99.01% from the prior year.
• Cash from Financing Activities was $88.2 million for Q1 2026 at Korro Bio, up from $380000.0 in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $144.6 million in Q4 2023 and bottomed at -$2.2 million in Q3 2023.
• A 5-year average of $21.6 million and a median of $186000.0 in 2022 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities sank 4014.29% — and 2024, when it soared 187755.56%.
• Korro Bio's Cash from Financing Activities stood at -$238000.0 in 2022, then soared by 60851.26% to $144.6 million in 2023, then tumbled by 99.36% to $932000.0 in 2024, then tumbled by 59.23% to $380000.0 in 2025, then surged by 23113.68% to $88.2 million in 2026.
• Business Quant data shows KRRO's Cash from Financing Activities at $88.2 million in Q1 2026, $380000.0 in Q4 2025, and $128000.0 in Q3 2025.